Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy

Research output: Contribution to journalJournal articlepeer-review


  1. High-Throughput UHPLC-MS to Screen Metabolites in Feces for Gut Metabolic Health

    Research output: Contribution to journalJournal articlepeer-review

  2. Targeting the Pentose Phosphate Pathway for SARS-CoV-2 Therapy

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

BACKGROUND: Clopidogrel and proton pump inhibitors (PPIs) are among the most used drugs in Denmark for which there exists pharmacogenomics (PGx)-based dosing guidelines and FDA annotations. In this study, we further scrutinized the use of clopidogrel and PPIs when prescriptions were redeemed from Danish Pharmacies alone or in combination in the Danish population and among persons with diabetes in Denmark. The focus deals with the potential of applying PGx-guided antiplatelet therapy taking both drug-drug interactions (DDI) and drug-gene interactions (DGI) into account.

METHODS: The Danish Register of Medicinal Product Statistics was the source to retrieve consumption data.

RESULTS: The consumption of PPIs and clopidogrel in terms of prevalence (users/1000 inhabitants) increased over a five-year period by 6.3% to 103.1 (PPIs) and by 41.7% to 22.1 (clopidogrel), respectively. The prevalence of the use of clopidogrel and PPIs in persons with diabetes are 3.8 and 2.1-2.8 times higher compared to the general population. When redeemed in combination, the prevalence increased to 4.7. The most used combination was clopidogrel and pantoprazole.

CONCLUSIONS: The use of clopidogrel and PPIs either alone or in combination is quite widespread, in particular among the elderly and persons with diabetes. This further supports the emerging need of accessing and accounting for not only DDI but also for applying PGx-guided drug therapy in clinical decision making for antiplatelet therapy with clopidogrel having a particular focus on persons with diabetes and the elderly.

Original languageEnglish
Article number96
Issue number2
Pages (from-to)1-11
Number of pages11
Publication statusPublished - 10 Feb 2021

    Research areas

  • Cardiovascular disease, Clopidogrel, Diabetics, Drug use, Drug–drug interactions, Drug–drug–gene interactions, Drug–gene interactions, El-derly, Pharmacogenomics, Polyphar-macy, Proton pump inhibitors (PPIs)

ID: 62270044